-- 加拿大國家銀行在隔夜報告中指出:“綜合來看,加拿大債券市場似乎正在應對地緣政治的不確定性(以及相當可觀的債券淨供應)。” 加拿大國家銀行指出,3月加拿大債券成交量約為2.25兆美元,「遠超過先前的月紀錄」。先前的最高紀錄是10月24日創下的2.01兆美元。該行表示,由於預算赤字和大規模資本需求推高了國內債券存量,二級市場交易量理應偏高。儘管如此,該行補充道,3月份的交易量激增“令人矚目”,經季節性調整後環比增長9%,同比增長24%。 在加拿大政府債券市場(超過80%的交易發生於此),加拿大國家銀行表示,做市商「無疑在一段時間內感受到了壓力,因為新聞頭條的波動很可能促使客戶朝著同一方向操作」。 “但經銷商群體提供了充足的流動性,這一點從加拿大政府債券(GoC Bond)的國內客戶交易量同比增長近60%即可看出。” 加拿大國家銀行指出,隨著國際對沖基金在加拿大政府債券市場日益活躍,非居民投資者的態度值得密切關注。 “但從我們的角度來看,非居民資金流動相對有序(而且幾乎不是單向的)。這算是經受住了考驗。” 加拿大國家銀行表示,加拿大信貸市場的狀況尚未顯著惡化,至少目前是如此。該行指出,剔除加拿大政府公債後,3月的債券成交量較去年同期成長6%,年增約15%。 「這比主權債券的成長速度要慢,但聯邦政府的債務規模畢竟成長更快,」該行補充道。 與加拿大政府債券一樣,加拿大國家銀行指出,經銷商為所有主要類型的客戶(無論是國內客戶還是國際客戶)促成了交易量的增加。報告也指出,波動性加劇的一個表現是,隨著債券價格從信用等級轉移到二級市場轉移,交易量明顯放緩。 「換句話說,低風險(或低貝塔係數)的政府債券利差產品在3月份的交易量相對活躍,而公司債券的交易量則較為平緩。但總的來說,該銀行認為這是一個運轉相對良好(且流動性尚可)的國內債券市場……考慮到政治風險可能持續加劇,這令人感到欣慰。」
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.